Evidence-Based Laboratory Medicine in Oncology Drug Development: From Biomarkers to Diagnostics | Zendy

Vijay Modur | Zendy; Eric Hailman | Zendy; J. Carl Barrett | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evidence-Based Laboratory Medicine in Oncology Drug Development: From Biomarkers to Diagnostics

Author(s) -

Vijay Modur,

Eric Hailman,

J. Carl Barrett

Publication year - 2012

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2012.191072

Subject(s) - drug development , biomarker , companion diagnostic , medicine , precision medicine , biomarker discovery , cancer biomarkers , personalized medicine , drug , translational research , cancer , cancer medicine , medical physics , bioinformatics , oncology , pathology , pharmacology , proteomics , biology , biochemistry , gene

The promise of targeted therapies in molecularly defined subsets of cancer has led to a transformation of the process of drug development in oncology. To target cancer successfully and precisely requires high-quality translational data. Such data can be generated by the use of biomarkers that answer key questions in drug development.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research